Department of Urology, Mayo Clinic, Rochester, MN, USA.
Department of Urology, Mayo Clinic, Rochester, MN, USA.
Eur Urol. 2020 Mar;77(3):373-379. doi: 10.1016/j.eururo.2019.04.001. Epub 2019 Apr 19.
Single-port robotic surgery is being adopted for various surgical procedures. There have been interest in and clinical use of single-port robot-assisted radical prostatectomy (spRARP), but little reported data on feasibility and early outcomes.
To describe our institution's initial experience with spRARP utilizing the da Vinci single-port (SP) robotic system.
DESIGN, SETTING, AND PARTICIPANTS: A retrospective review of the initial experience of three high-volume robotic prostate surgeons performing an spRARP utilizing the da Vinci SP robotic system was carried out.
An spRARP using the da Vinci SP robotic system was performed following the traditional retropubic or Retzius-sparing approach.
Patient demographics, operative time, blood loss, postoperative hospital stay, complications, and catheter duration were obtained and analyzed.
In a cohort of 49 patients undergoing spRARP, median age was 62yr and prostate-specific antigen 6.4. Of the patients, 35 (71%) had cT1c disease on presentation, 92% had Gleason grade group ≥2 disease, and 85% were pT2 on final pathology. Median operative time was 161min. Median blood loss was 200ml. Seven Retzius-sparing cases were performed. Four Clavien 2 complications occurred (complication rate 8.1%). Median hospital stay was 1d and median catheter duration 7d. Operative time was <200min for all three surgeons by their third case.
The da Vinci SP system spRARP is safe and feasible, with acceptable operative time and blood loss. Further research is needed to establish noninferiority to the da Vinci Xi and Si systems, and impact of spRARP on patient-assessed cosmesis and pain.
Robotic prostatectomy using a purpose-built da Vinci single-port robotic system is safe and feasible, and warrants further study to determine whether it can improve patient outcomes.
单孔机器人手术正被应用于各种外科手术中。单孔机器人辅助根治性前列腺切除术(spRARP)已受到关注并应用于临床,但有关其可行性和早期结果的报道较少。
描述我们机构使用达芬奇单孔(SP)机器人系统进行 spRARP 的初步经验。
设计、地点和参与者:对三位高容量机器人前列腺外科医生使用达芬奇 SP 机器人系统进行 spRARP 的初始经验进行了回顾性分析。
采用达芬奇 SP 机器人系统进行 spRARP,遵循传统的经耻骨后或保留耻骨上间隙入路。
获得并分析了患者的人口统计学资料、手术时间、出血量、术后住院时间、并发症和导管留置时间。
在 49 例接受 spRARP 的患者队列中,中位年龄为 62 岁,前列腺特异性抗原为 6.4。患者中,35 例(71%)在就诊时为 cT1c 期疾病,92%有 Gleason 分级≥2 级疾病,85%在最终病理上为 pT2 期。中位手术时间为 161 分钟。中位出血量为 200ml。7 例采用保留耻骨上间隙入路。4 例发生 Clavien 2 级并发症(并发症发生率为 8.1%)。中位住院时间为 1 天,中位导管留置时间为 7 天。所有三位外科医生在他们的第三例手术中,手术时间均<200 分钟。
达芬奇 SP 系统 spRARP 是安全可行的,具有可接受的手术时间和出血量。需要进一步研究以确定其是否不劣于达芬奇 Xi 和 Si 系统,以及 spRARP 对患者评估美容和疼痛的影响。
使用专门设计的达芬奇单孔机器人系统进行机器人前列腺切除术是安全可行的,值得进一步研究,以确定其是否能改善患者的预后。